CG201 is covered by issued patents licensed exclusively to CGT that will maintain patent coverage for the product until at least 2019. CGT is pursuing additional patent coverage for CG201.

Several delivery systems have been tested for increasing and prolonging the antibody-mediated immunity provided by CG201 and by other vaccines as well. CGT’s clinical testing program will provide human data for the first time for our delivery systems, demonstrating their clinical potential and clearing the way for their use with other vaccines.